High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells

Mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we searched for small molecules that selectively inhibit the growth of CALR...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Ruochen, Kutzner, Leon, Koren, Anna, Runggatscher, Kathrin, Májek, Peter, Müller, André C., Schuster, Michael, Bock, Christoph, Loizou, Joanna I., Kubicek, Stefan, Kralovics, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325683/
https://www.ncbi.nlm.nih.gov/pubmed/34333533
http://dx.doi.org/10.1038/s41408-021-00531-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325683/
https://www.ncbi.nlm.nih.gov/pubmed/34333533
http://dx.doi.org/10.1038/s41408-021-00531-2

Ejemplares similares